Ulcerative Colitis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Ulcerative Colitis Overview

Ulcerative colitis is a chronic disease of the large intestine, in which the lining of the colon becomes inflamed and develops tiny open sores or ulcers. Those ulcers produce pus and mucous, which causes abdominal pain. It usually begins in the rectum and spreads upwards. The inflammation causes the bowel to move its content rapidly and empty frequently. Ulcerative colitis begins gradually and becomes worse over the period of time. Ulcerative colitis is also known as inflammatory bowel disease.

“Ulcerative Colitis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ulcerative Colitis Market.

The Ulcerative Colitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Ulcerative Colitis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Ulcerative Colitis treatment therapies with a considerable amount of success over the years. Ulcerative Colitis Key players such as – NuBiyota, Adiso Therapeutics, Landos Biopharma, Prometheus Biosciences, OSE Immunotherapeutics, AstraZeneca, Morphic Therapeutics, AbbVie, InDex Pharmaceuticals, Pfizer, Johnson & Johnson, Takeda, Pfizer, Eli Lilly, EA Pharma, Galapagos, Bristol-Myers Squibb, Arena Pharmaceuticals, and others, are developing therapies for the Ulcerative Colitis treatment 

• Ulcerative Colitis Emerging therapies such as – MET-2, BT051, NX-13, PRA023, OSE-127, Brazikumab, MORF-057, Risankizumab, Cobitolimod, Etrasimod, and others are expected to have a significant impact on the Ulcerative Colitis market in the coming years.
• In November 2021, InDex Pharmaceuticals initiated a randomised double-blind placebo-controlled Phase III clinical study to evaluate the efficacy and safety of Cobitolimod as an induction and maintenance therapy in participants with moderate to severe active left-sided Ulcerative Colitis   
• In March 2020, AstraZeneca initiated a Phase II open-label, long-term extension safety study of Brazikumab in participants with moderately to severely active Ulcerative Colitis

Route of Administration

Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Ulcerative Colitis Pipeline Therapeutics Assessment

• Ulcerative Colitis Assessment by Product Type
• Ulcerative Colitis By Stage and Product Type
• Ulcerative Colitis Assessment by Route of Administration
• Ulcerative Colitis By Stage and Route of Administration
• Ulcerative Colitis Assessment by Molecule Type
• Ulcerative Colitis by Stage and Molecule Type

DelveInsight’s Ulcerative Colitis Report covers around products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Ulcerative Colitis Drugs Under Different Phases of Clinical Development Include:

• MET-2: NuBiyota
• BT051: Adiso Therapeutics
• NX-13: Landos Biopharma
• PRA023: Prometheus Biosciences
• OSE-127: OSE Immunotherapeutics
• Brazikumab: AstraZeneca
• MORF-057: Morphic Therapeutics
• Risankizumab: AbbVie
• Cobitolimod: InDex Pharmaceuticals
• Etrasimod: Pfizer

Get a Free Sample PDF Report to know more about Ulcerative Colitis Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight

Ulcerative Colitis Pipeline Analysis:

The Ulcerative Colitis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Ulcerative Colitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ulcerative Colitis Treatment.
• Ulcerative Colitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ulcerative Colitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ulcerative Colitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Ulcerative Colitis product details are provided in the report. Download the Ulcerative Colitis pipeline report to learn more about the emerging Ulcerative Colitis therapies

Ulcerative Colitis Pipeline Market Drivers

• Increasing awareness and R&D investment
• Emergence of large number of novel pipeline molecules with great market potential

Ulcerative Colitis Pipeline Market Barriers

• Side effects associated with the treatment
• High cost Ulcerative Colitis treatment

Scope of Ulcerative Colitis Pipeline Drug Insight    

• Coverage: Global
• Key Ulcerative Colitis Companies: NuBiyota, Adiso Therapeutics, Landos Biopharma, Prometheus Biosciences, OSE Immunotherapeutics, AstraZeneca, Morphic Therapeutics, AbbVie, InDex Pharmaceuticals, Pfizer, Johnson & Johnson, Takeda, Pfizer, Eli Lilly, EA Pharma, Galapagos, Bristol-Myers Squibb, Arena Pharmaceuticals, and others
• Key Ulcerative Colitis Therapies: MET-2, BT051, NX-13, PRA023, OSE-127, Brazikumab, MORF-057, Risankizumab, Cobitolimod, Etrasimod, and others
• Ulcerative Colitis Therapeutic Assessment: Ulcerative Colitis current marketed and Ulcerative Colitis emerging therapies
• Ulcerative Colitis Market Dynamics: Ulcerative Colitis market drivers and Ulcerative Colitis market barriers 

Request for Sample PDF Report for Ulcerative Colitis Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Ulcerative Colitis drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services